LONDON, Dec 16 (Reuters) - The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker ...

As of midyear, Maryland’s biomanufacturing footprint had a 1.1% vacancy rate, while its R&D footprint sat at 10.8% vacant, ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...

AstraZeneca, Eastman, Kraft Heinz, and P&G have been recognized for their outstanding contribution at the recent OMP ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...